Literature DB >> 15330805

Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL).

G Perea1, A Altés, M Bellido, A Aventín, R Bordes, R Ayats, A F Remacha, I Espinosa, J Briones, J Sierra, J F Nomdedéu.   

Abstract

AIM: To determine the efficacy of flow cytometry (FC) in the assessment of bone marrow (BM) in B-cell non-Hodgkin lymphoma (B-NHL). FC is a common practice, but is far from being validated. METHODS AND
RESULTS: Morphological analysis and FC immunophenotyping were performed on 421 samples. T-cell lymphomas, Hodgkin's disease, chronic lymphocytic leukaemia and hairy cell leukaemia were not included in the study. Clonality was assessed by the standard kappa/lambda/CD19 test. Aberrant immunophenotypes present in the B-cell subpopulation were also investigated. A double-step procedure was employed in all cases to increase the sensitivity of the FC procedure. Of 380 evaluable samples, 188 corresponded to follicular lymphoma (FL), 58 to diffuse large B-cell lymphoma (DLBCL), 57 to mantle cell lymphoma (MCL), seven to Burkitt's lymphoma and the remaining 70 samples to other low-grade lymphomas. Morphological marrow infiltration was found in 148 cases, and flow immunophenotyping identified 138 cases with BM involvement. A concordance between the two methods was detected in 298 cases (79%). There was a discordance in 82 cases (21%): morphology positive/FC negative in 46 cases and morphology negative/FC positive in 36 (61% of all cases with discordance were from FL). There was no difference in outcome when patients with discordances were compared with patients without discordances.
CONCLUSIONS: Most samples showed concordance between morphological and FC results. FC identified BM involvement in the absence of morphological infiltration. Morphology/FC discordance seems to have no influence on the outcome of FL patients. Copyright 2004 Blackwell Publishing Limited

Entities:  

Mesh:

Year:  2004        PMID: 15330805     DOI: 10.1111/j.1365-2559.2004.01937.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution.

Authors:  M A Cabezas-Quintario; P Gomez; V Yuste-Del Pozo; A L Valencia-Mesa; G Sosa; P Ricard; A I Hijas-Gómez; F Pinedo; M Arguelles
Journal:  Clin Transl Oncol       Date:  2015-08-27       Impact factor: 3.405

2.  Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).

Authors:  Dipti Talaulikar; Jane Esther Dahlstrom; Bruce Shadbolt; Amy Broomfield; Anne McDonald
Journal:  J Histochem Cytochem       Date:  2008-06-23       Impact factor: 2.479

3.  If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.

Authors:  Patrizia Mancuso; Angelica Calleri; Pierluigi Antoniotti; Jessica Quarna; Giancarlo Pruneri; Francesco Bertolini
Journal:  BMC Cancer       Date:  2010-11-24       Impact factor: 4.430

4.  Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma.

Authors:  Ellen Berget; Lars Helgeland; Knut Liseth; Turid Løkeland; Anders Molven; Olav Karsten Vintermyr
Journal:  J Clin Pathol       Date:  2014-09-18       Impact factor: 3.411

5.  Bone marrow flow cytometry in staging of patients with B-cell non-Hodgkin lymphoma.

Authors:  Borahm Kim; Seung-Tae Lee; Hee-Jin Kim; Sun Hee Kim
Journal:  Ann Lab Med       Date:  2015-02-12       Impact factor: 3.464

6.  Bone Marrow Involvement by Aggressive B Cell Lymphoma Undetected by Aspirate Immunophenotyping.

Authors:  Habib Moshref Razavi
Journal:  J Hematol       Date:  2021-02-06

7.  Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).

Authors:  Dipti Talaulikar; Bruce Shadbolt; Jane E Dahlstrom; Anne McDonald
Journal:  J Hematol Oncol       Date:  2009-11-22       Impact factor: 17.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.